Previous 10 | Next 10 |
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two ...
SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the formation of a scientific advisory board to help guide the companyȁ...
The Food and Drug Administration (FDA) granted Turning Point Therapeutics ( TPTX +2.0% ) a third Fast-Track designation to its lead drug candidate, repotrectinib for treatment of patients with advanced solid tumors that have an NTRK gene fusion. More news on: Turning Point Therape...
SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted a third Fast-Track designatio...
Turning Point reports positive data for tumor drug candidate Turning Point Therapeutics ( TPTX ) reported positive preliminary data from its Phase 2 clinical trial TRIDENT-1. The trial is designed to assess the potential of repotrectinib in treating patients with ALK-, ROS1- or NTRK-3-mu...
Turning Point Therapeutics (NASDAQ: TPTX ) announces positive preliminary results from a Phase 2 clinical trial, TRIDENT-1 , evaluating lead candidate repotrectinib in patients with ALK-, ROS1- or NTRK-3-mutation-positive solid tumors. More news on: Turning Point Therapeutics, Inc., H...
ROS1+ TKI-Naïve Non-Small Cell Lung Cancer Confirmed Objective Response Rate is 86 Percent ROS1+ TKI-Pretreated Non-Small Cell Lung Cancer with One Prior TKI and Prior Chemotherapy, Confirmed Objective Response Rate is 40 Percent ROS1+ TKI-Pretre...
Early Interim Data from Registrational Phase 2 TRIDENT-1 Study of Lead Drug Candidate Repotrectinib Anticipated in Third Quarter Four Clinical Studies of Three Drug Candidates Ongoing; Early Interim TPX-0022 Data Anticipated in Fourth Quarter Cash, Cash Equiv...
SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Heather Adams as vice president of Human Resources, effec...
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Andrew Partridge as executive vice president and chief co...
News, Short Squeeze, Breakout and More Instantly...
Turning Point Therapeutics Inc. Company Name:
TPTX Stock Symbol:
NYSE Market:
Turning Point Therapeutics Inc. Website:
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET...
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug Administ...